Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 167

1.

Retroperitoneal primitive neuroectodermal tumor (PNET): case report and review of literature.

Koch A, Frigo S, Lecointre L, Hummel M, Akladios CY, Bergerat JP, Noël G, Wattiez A.

Eur J Gynaecol Oncol. 2017;38(2):314-318. Review.

PMID:
29953804
2.

[Pertuzumab and solid tumors: perspectives].

Barthélémy P, Leblanc J, Wendling F, Wissler MP, Bergerat JP.

Bull Cancer. 2014 Dec;101(12):1114-21. doi: 10.1684/bdc.2014.2026. French.

PMID:
25532690
3.

First report of trastuzumab treatment after postoperative Takotsubo cardiomyopathy.

Burgy M, Brossat H, Barthelemy P, Imperiale A, Trinh A, Hazam CA, Bergerat JP, Mathelin C.

Anticancer Res. 2014 Jul;34(7):3579-82.

PMID:
24982372
4.

Isolated cerebellar metastasis from prostate adenocarcinoma diagnosed by 18F-fluorocholine PET/CT: a rare but not impossible complication.

Imperiale A, Bergerat JP, Saussine C, Abu Eid M, Kehrli P, Namer IJ.

Eur J Nucl Med Mol Imaging. 2014 Feb;41(2):397-8. doi: 10.1007/s00259-013-2577-6. Epub 2013 Oct 1. No abstract available.

PMID:
24081449
5.

Constitutively active androgen receptor variants upregulate expression of mesenchymal markers in prostate cancer cells.

Cottard F, Asmane I, Erdmann E, Bergerat JP, Kurtz JE, Céraline J.

PLoS One. 2013 May 2;8(5):e63466. doi: 10.1371/journal.pone.0063466. Print 2013.

6.

Duration of adjuvant trastuzumab treatment in routine practice.

Montserrat M, Leveque D, Barthelemy P, Bergerat JP.

Anticancer Res. 2012 Oct;32(10):4585-8.

PMID:
23060590
7.

Risk of hormone escape in a human prostate cancer model depends on therapy modalities and can be reduced by tyrosine kinase inhibitors.

Guyader C, Céraline J, Gravier E, Morin A, Michel S, Erdmann E, de Pinieux G, Cabon F, Bergerat JP, Poupon MF, Oudard S.

PLoS One. 2012;7(8):e42252. doi: 10.1371/journal.pone.0042252. Epub 2012 Aug 6.

8.

Insulin-like growth factor type 1 receptor (IGF-1R) exclusive nuclear staining: a predictive biomarker for IGF-1R monoclonal antibody (Ab) therapy in sarcomas.

Asmane I, Watkin E, Alberti L, Duc A, Marec-Berard P, Ray-Coquard I, Cassier P, Decouvelaere AV, Ranchère D, Kurtz JE, Bergerat JP, Blay JY.

Eur J Cancer. 2012 Nov;48(16):3027-35. doi: 10.1016/j.ejca.2012.05.009. Epub 2012 Jun 7.

PMID:
22682017
9.

Bevacizumab plus microtubule targeting agents in heavily pre-treated ovarian cancer patients: a retrospective study.

Asmane I, Kurtz JE, Bajard A, Guastalla JP, Meeus P, Tredan O, Labidi Galy I, Moullet I, Ardisson P, Vincent L, Coeffic D, Dufresne A, Bergerat JP, Ray-Coquard I.

Bull Cancer. 2011 Oct;98(9):80-9. doi: 10.1684/bdc.2011.1436.

10.

Off-label use of oxaliplatin in patients with metastatic breast cancer.

Delpeuch A, Leveque D, Rob L, Bergerat JP.

Anticancer Res. 2011 May;31(5):1765-7.

PMID:
21617237
11.

New strategies for medical management of castration-resistant prostate cancer.

Asmane I, Céraline J, Duclos B, Rob L, Litique V, Barthélémy P, Bergerat JP, Dufour P, Kurtz JE.

Oncology. 2011;80(1-2):1-11. doi: 10.1159/000323495. Epub 2011 May 16. Review.

PMID:
21577012
12.

[Potential clinical impact of therapeutic education in patients treated with anticancer drugs].

Santucci R, Aatmani AE, Lescoute A, Levêque D, Serra S, Bergerat JP, Beretz L, Herbrecht R.

Bull Cancer. 2011 Feb;98(2):176-81. doi: 10.1684/bdc.2011.1308. French.

13.

Gestational choriocarcinoma transmission following multiorgan donation.

Braun-Parvez L, Charlin E, Caillard S, Ducloux D, Wolf P, Rolle F, Golfier F, Flicoteaux H, Bergerat JP, Moulin B.

Am J Transplant. 2010 Nov;10(11):2541-6. doi: 10.1111/j.1600-6143.2010.03275.x.

14.

Adjuvant chemotherapy in elderly patients with early breast cancer. Impact of age and comprehensive geriatric assessment on tumor board proposals.

Barthélémy P, Heitz D, Mathelin C, Polesi H, Asmane I, Litique V, Rob L, Bergerat JP, Kurtz JE.

Crit Rev Oncol Hematol. 2011 Aug;79(2):196-204. doi: 10.1016/j.critrevonc.2010.06.005. Epub 2010 Jul 23. Review.

PMID:
20655243
15.

Successful treatment of a granulocytic sarcoma of the uterine cervix in complete remission at six-year follow-up.

Kim SC, Natarajan-Ame S, Lioure B, Chenard MP, Duclos B, Herbrecht R, Bergerat JP.

J Oncol. 2010;2010:812424. doi: 10.1155/2010/812424. Epub 2010 Apr 29.

16.

Severe intoxication with methotrexate possibly associated with concomitant use of proton pump inhibitors.

Santucci R, Levêque D, Kemmel V, Lutz P, Gérout AC, N'guyen A, Lescoute A, Schneider F, Bergerat JP, Herbrecht R.

Anticancer Res. 2010 Mar;30(3):963-5.

PMID:
20393020
17.

A V530I Mutation in c-KIT Exon 10 Is Associated to Imatinib Response in Extraabdominal Aggressive Fibromatosis.

Kurtz JE, Asmane I, Voegeli AC, Neuville A, Dufresne A, Litique V, Chevreau C, Bergerat JP.

Sarcoma. 2010;2010:458156. doi: 10.1155/2010/458156. Epub 2010 Mar 17.

18.

Role of cationic channel TRPV2 in promoting prostate cancer migration and progression to androgen resistance.

Monet M, Lehen'kyi V, Gackiere F, Firlej V, Vandenberghe M, Roudbaraki M, Gkika D, Pourtier A, Bidaux G, Slomianny C, Delcourt P, Rassendren F, Bergerat JP, Ceraline J, Cabon F, Humez S, Prevarskaya N.

Cancer Res. 2010 Feb 1;70(3):1225-35. doi: 10.1158/0008-5472.CAN-09-2205. Epub 2010 Jan 26.

19.

Potential pharmacokinetic interactions affecting antitumor drug disposition in cancer patients.

Lemachatti J, Levêque D, Beretz L, Bergerat JP.

Anticancer Res. 2009 Nov;29(11):4741-4.

20.

Identification of novel truncated androgen receptor (AR) mutants including unreported pre-mRNA splicing variants in the 22Rv1 hormone-refractory prostate cancer (PCa) cell line.

Marcias G, Erdmann E, Lapouge G, Siebert C, Barthélémy P, Duclos B, Bergerat JP, Céraline J, Kurtz JE.

Hum Mutat. 2010 Jan;31(1):74-80. doi: 10.1002/humu.21138.

PMID:
19830810
21.

Paralytic ileus possibly associated with interaction between ritonavir/lopinavir and vincristine.

Levêque D, Santucci R, Pavillet J, Herbrecht R, Bergerat JP.

Pharm World Sci. 2009 Dec;31(6):619-21. doi: 10.1007/s11096-009-9323-y. Epub 2009 Sep 10.

PMID:
19757141
22.

Adjuvant chemotherapy in elderly patients with colorectal cancer. A retrospective analysis of the implementation of tumor board recommendations in a single institution.

Kurtz JE, Heitz D, Serra S, Brigand C, Juif V, Podelski V, Meyer P, Litique V, Bergerat JP, Rohr S, Dufour P.

Crit Rev Oncol Hematol. 2010 Jun;74(3):211-7. doi: 10.1016/j.critrevonc.2009.05.003. Epub 2009 Jun 26. Review.

PMID:
19560368
23.

Geriatric oncology, general practitioners and specialists: current opinions and unmet needs.

Kurtz JE, Heitz D, Enderlin P, Imbert F, Nehme H, Bergerat JP, Dufour P.

Crit Rev Oncol Hematol. 2010 Jul;75(1):47-57. doi: 10.1016/j.critrevonc.2009.03.002. Epub 2009 Apr 5.

PMID:
19349189
24.
25.

Factors associated with overall and attributable mortality in invasive aspergillosis.

Nivoix Y, Velten M, Letscher-Bru V, Moghaddam A, Natarajan-Amé S, Fohrer C, Lioure B, Bilger K, Lutun P, Marcellin L, Launoy A, Freys G, Bergerat JP, Herbrecht R.

Clin Infect Dis. 2008 Nov 1;47(9):1176-84. doi: 10.1086/592255.

PMID:
18808352
26.

Pleiotropic functional properties of androgen receptor mutants in prostate cancer.

Bergerat JP, Céraline J.

Hum Mutat. 2009 Feb;30(2):145-57. doi: 10.1002/humu.20848. Review.

PMID:
18800375
27.

Clinical pharmacology of trastuzumab.

Levêque D, Gigou L, Bergerat JP.

Curr Clin Pharmacol. 2008 Jan;3(1):51-5. Review.

PMID:
18690878
28.

Diffuse primary angiosarcoma of the pleura: a case report and review of the literature.

Kurtz JE, Serra S, Duclos B, Brolly F, Dufour P, Bergerat JP.

Sarcoma. 2004;8(4):103-6. doi: 10.1080/1357-7140400003596.

29.

Specific properties of a C-terminal truncated androgen receptor detected in hormone refractory prostate cancer.

Lapouge G, Marcias G, Erdmann E, Kessler P, Cruchant M, Serra S, Bergerat JP, Céraline J.

Adv Exp Med Biol. 2008;617:529-34. doi: 10.1007/978-0-387-69080-3_53.

PMID:
18497078
30.

Effect of pO2 on antitumor drug cytotoxicity on MDR and non-MDR variants selected from the LoVo metastatic colon carcinoma cell line.

Lelong-Rebel I, Brisson C, Fabre M, Bergerat JP, Rebel G.

Anticancer Res. 2008 Jan-Feb;28(1A):55-68.

31.

[Late outcome of 89 patients with soft-tissue sarcomas treated by surgery and three different radiotherapy schedules].

Heymann S, Jung GM, Simon P, Bergerat JP, Borel C, Di Marco A, Kurtz JE, Marcellin L, Ghnassia JP, Dufour P, Noël G.

Cancer Radiother. 2007 Dec;11(8):443-51. Epub 2007 Nov 5. French.

PMID:
17981486
32.

A splicing variant of the androgen receptor detected in a metastatic prostate cancer exhibits exclusively cytoplasmic actions.

Jagla M, Fève M, Kessler P, Lapouge G, Erdmann E, Serra S, Bergerat JP, Céraline J.

Endocrinology. 2007 Sep;148(9):4334-43. Epub 2007 May 31.

PMID:
17540719
33.

Unexpected paracrine action of prostate cancer cells harboring a new class of androgen receptor mutation--a new paradigm for cooperation among prostate tumor cells.

Lapouge G, Erdmann E, Marcias G, Jagla M, Monge A, Kessler P, Serra S, Lang H, Jacqmin D, Bergerat JP, Céraline J.

Int J Cancer. 2007 Sep 15;121(6):1238-44.

34.

The cytotoxicity of high-linear energy transfer radiation is reinforced by oxaliplatin in human glioblastoma cells.

Benzina S, Debomy F, Bergerat JP, Denis JM, Gueulette J, Dufour P, Bischoff P.

Cancer Lett. 2007 Aug 28;254(1):54-62. Epub 2007 Mar 26.

PMID:
17383816
35.

[Aromatase inhibitors in the adjuvant treatment of early breast cancer. Is there still a place for tamoxifen?].

Bergerat JP.

Presse Med. 2007 Feb;36(2 Pt 2):333-40. Epub 2007 Jan 8. Review. French.

PMID:
17258683
36.

Long-term survival in post-transplant lymphoproliferative disorders with a dose-adjusted ACVBP regimen.

Fohrer C, Caillard S, Koumarianou A, Ellero B, Woehl-Jaeglé ML, Meyer C, Epailly E, Chenard MP, Lioure B, Natarajan-Ame S, Maloisel F, Lutun P, Kessler R, Moulin B, Bergerat JP, Wolf P, Herbrecht R.

Br J Haematol. 2006 Sep;134(6):602-12. Epub 2006 Aug 2.

PMID:
16889621
37.

Potentiation of apple procyanidin-triggered apoptosis by the polyamine oxidase inactivator MDL 72527 in human colon cancer-derived metastatic cells.

Gossé F, Roussi S, Guyot S, Schoenfelder A, Mann A, Bergerat JP, Seiler N, Raul F.

Int J Oncol. 2006 Aug;29(2):423-8.

PMID:
16820885
38.

[A cytological, immunophenotypical and cytogenetical study of 136 consecutive cases of B-cell chronic lymphoid hemopathies].

Struski S, Leymarie V, Helias C, Falkenrodt A, Fohrer C, Audhuy B, Lioure B, Moskovtchenko P, Mazurier I, Galoisy AC, Gervais C, Mauvieux L, Herbrecht R, Bergerat JP, Lessard M.

Pathol Biol (Paris). 2007 Feb;55(1):59-72. Epub 2006 May 11. French.

PMID:
16690228
39.

Cell death induced in a human glioblastoma cell line by p(65)+Be neutrons combined with cisplatin.

Benzina S, Fischer B, Miternique-Grosse A, Dufour P, Denis JM, Bergerat JP, Gueulette J, Bischoff P.

Life Sci. 2006 Jul 4;79(6):513-8. Epub 2006 Mar 3.

PMID:
16516239
40.

Unfaithfulness and promiscuity of a mutant androgen receptor in a hormone-refractory prostate cancer.

Monge A, Jagla M, Lapouge G, Sasorith S, Cruchant M, Wurtz JM, Jacqmin D, Bergerat JP, Céraline J.

Cell Mol Life Sci. 2006 Feb;63(4):487-97.

PMID:
16456618
41.

Liver abscess due to clostridium septicum. A case report and review of the literature.

Kurtz JE, Claudel L, Collard O, Limacher JM, Bergerat JP, Dufour P.

Hepatogastroenterology. 2005 Sep-Oct;52(65):1557-8.

PMID:
16201118
42.

Chemotherapy for breast cancer during pregnancy.

Mathelin C, Annane K, Dufour P, Liegeois P, Bergerat JP.

Eur J Obstet Gynecol Reprod Biol. 2005 Dec 1;123(2):260-2. Epub 2005 Jul 15. No abstract available.

PMID:
16024158
43.

Fast neutrons-induced apoptosis is Fas-independent in lymphoblastoid cells.

Fischer B, Benzina S, Jeannequin P, Dufour P, Bergerat JP, Denis JM, Gueulette J, Bischoff PL.

Biochem Biophys Res Commun. 2005 Aug 26;334(2):533-42.

PMID:
16018969
44.

Cisplatin-induced genes as potential markers for thyroid cancer.

Lapouge G, Millon R, Muller D, Abecassis J, Eber M, Bergerat JP, Klein-Soyer C.

Cell Mol Life Sci. 2005 Jan;62(1):53-64.

PMID:
15619007
45.

Cisplatin enhances the cytotoxicity of fast neutrons in a murine lymphoma cell line.

Fischer B, Benzina S, Ganansia-Leymarie V, Denis JM, Bergerat JP, Dufour P, Gueulette J, Bischoff P.

Can J Physiol Pharmacol. 2004 Feb;82(2):140-5.

PMID:
15052295
46.

[Saccharomyces cerevisiae: an efficient tool and model system for anticancer research].

Kurtz JE, Dufour P, Duclos B, Bergerat JP, Exinger F.

Bull Cancer. 2004 Feb;91(2):133-9. Review. French.

47.

Conflicting effects of caffeine on apoptosis and clonogenic survival of human K1 thyroid carcinoma cell lines with different p53 status after exposure to cisplatin or UVc irradiation.

Deplanque G, Céraline J, Lapouge G, Dufour P, Bergerat JP, Klein-Soyer C.

Biochem Biophys Res Commun. 2004 Feb 20;314(4):1100-6.

PMID:
14751246
48.

Constitutive activation of the androgen receptor by a point mutation in the hinge region: a new mechanism for androgen-independent growth in prostate cancer.

Céraline J, Cruchant MD, Erdmann E, Erbs P, Kurtz JE, Duclos B, Jacqmin D, Chopin D, Bergerat JP.

Int J Cancer. 2004 Jan 1;108(1):152-7.

49.

Caspase 8-mediated cleavage of the pro-apoptotic BCL-2 family member BID in p53-dependent apoptosis.

Fischer B, Coelho D, Dufour P, Bergerat JP, Denis JM, Gueulette J, Bischoff P.

Biochem Biophys Res Commun. 2003 Jun 27;306(2):516-22.

PMID:
12804595
50.

Signal transduction pathways of taxanes-induced apoptosis.

Ganansia-Leymarie V, Bischoff P, Bergerat JP, Holl V.

Curr Med Chem Anticancer Agents. 2003 Jul;3(4):291-306. Review.

PMID:
12769774

Supplemental Content

Loading ...
Support Center